Zamaglutenase - Takeda
Alternative Names: Kuma-062; KumaMax; PvP-001; PvP-002; Synthetic enzymes - PvP Biologics; TAK-062Latest Information Update: 04 Jul 2025
At a glance
- Originator University of Washington
- Developer PvP Biologics
- Class Anti-inflammatories; Digestion aids; Enzymes; Peptide hydrolases; Proteins; Recombinant proteins
- Mechanism of Action Gliadin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coeliac disease
Most Recent Events
- 04 Jul 2025 Discontinued - Phase-II for Coeliac disease (In adolescents, In the elderly, In adults) in USA (PO) (Takeda pipeline, July 2025)
- 06 Nov 2024 Takeda completes phase-II clinical trials in Coeliac disease (In adolescents, In adults, In the elderly) in USA (PO) (NCT05353985)
- 30 Jun 2022 Phase-II clinical trials in Coeliac disease (In adolescents, In adults, In the elderly) in USA (PO) (NCT05353985)